Advances and perspectives in the molecular diagnosis of head and neck cancer

Wojciech Mydlarz, Patrick T. Hennessey, Joseph A. Califano

Research output: Contribution to journalArticle

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a debilitating and lethal disease. Despite significant advances in radiotherapy and surgical management, the 5-year survival rate for head and neck cancer has remained a dismal 50%. Advances in early detection have been made, but to improve patient outcomes better biomarkers and targeted therapeutic agents are needed. New biomarkers can improve early detection and provide data to optimize therapeutic strategy and patient survival, and could lead to potentially effective targeted therapies. To report the advances in the discovery of new biomarkers for HNSCC, and review the potential utility of biomarkers in the molecular diagnosis of HNSCC. A review of the English literature (PubMed) from 1980 to 2009. At present, the most widely accepted biomarker for HNSCC is high-risk HPV status. EGFR is another promising biomarker; however, further research is necessary to determine its prognostic benefit. A large number of promising biomarker candidates are now being evaluated, including epigenetic, expression and genomic-based markers. Studies to validate the sensitivity and specificity of these biomarkers in clinical samples from adequately powered prospective cohorts are needed for successful translation of these findings into potential molecular diagnostic, prognostic and therapeutic biomarkers for HNSCC.

Original languageEnglish (US)
Pages (from-to)53-65
Number of pages13
JournalExpert Opinion on Medical Diagnostics
Volume4
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Biomarkers
Head and Neck Neoplasms
Molecular Pathology
Radiotherapy
Therapeutics
PubMed
Epigenomics
Survival Rate
Carcinoma, squamous cell of head and neck
Epithelial Cells
Sensitivity and Specificity
Survival
Research

Keywords

  • Biomarkers
  • Diagnosis
  • DNA methylation
  • Epidermal growth factor receptor
  • Epigenetics
  • Head and neck cancer
  • Human papillomavirus
  • Loss of heterozygosity
  • MicroRNA
  • Molecular biology
  • Proteomics
  • RNA

ASJC Scopus subject areas

  • Biomedical Engineering
  • Medicine(all)
  • Biochemistry, medical
  • Molecular Medicine

Cite this

Advances and perspectives in the molecular diagnosis of head and neck cancer. / Mydlarz, Wojciech; Hennessey, Patrick T.; Califano, Joseph A.

In: Expert Opinion on Medical Diagnostics, Vol. 4, No. 1, 01.2010, p. 53-65.

Research output: Contribution to journalArticle

Mydlarz, Wojciech ; Hennessey, Patrick T. ; Califano, Joseph A. / Advances and perspectives in the molecular diagnosis of head and neck cancer. In: Expert Opinion on Medical Diagnostics. 2010 ; Vol. 4, No. 1. pp. 53-65.
@article{82ed13c3f4e84d92acedc3f13b58d952,
title = "Advances and perspectives in the molecular diagnosis of head and neck cancer",
abstract = "Head and neck squamous cell carcinoma (HNSCC) is a debilitating and lethal disease. Despite significant advances in radiotherapy and surgical management, the 5-year survival rate for head and neck cancer has remained a dismal 50{\%}. Advances in early detection have been made, but to improve patient outcomes better biomarkers and targeted therapeutic agents are needed. New biomarkers can improve early detection and provide data to optimize therapeutic strategy and patient survival, and could lead to potentially effective targeted therapies. To report the advances in the discovery of new biomarkers for HNSCC, and review the potential utility of biomarkers in the molecular diagnosis of HNSCC. A review of the English literature (PubMed) from 1980 to 2009. At present, the most widely accepted biomarker for HNSCC is high-risk HPV status. EGFR is another promising biomarker; however, further research is necessary to determine its prognostic benefit. A large number of promising biomarker candidates are now being evaluated, including epigenetic, expression and genomic-based markers. Studies to validate the sensitivity and specificity of these biomarkers in clinical samples from adequately powered prospective cohorts are needed for successful translation of these findings into potential molecular diagnostic, prognostic and therapeutic biomarkers for HNSCC.",
keywords = "Biomarkers, Diagnosis, DNA methylation, Epidermal growth factor receptor, Epigenetics, Head and neck cancer, Human papillomavirus, Loss of heterozygosity, MicroRNA, Molecular biology, Proteomics, RNA",
author = "Wojciech Mydlarz and Hennessey, {Patrick T.} and Califano, {Joseph A.}",
year = "2010",
month = "1",
doi = "10.1517/17530050903338068",
language = "English (US)",
volume = "4",
pages = "53--65",
journal = "Expert Opinion on Medical Diagnostics",
issn = "1753-0059",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Advances and perspectives in the molecular diagnosis of head and neck cancer

AU - Mydlarz, Wojciech

AU - Hennessey, Patrick T.

AU - Califano, Joseph A.

PY - 2010/1

Y1 - 2010/1

N2 - Head and neck squamous cell carcinoma (HNSCC) is a debilitating and lethal disease. Despite significant advances in radiotherapy and surgical management, the 5-year survival rate for head and neck cancer has remained a dismal 50%. Advances in early detection have been made, but to improve patient outcomes better biomarkers and targeted therapeutic agents are needed. New biomarkers can improve early detection and provide data to optimize therapeutic strategy and patient survival, and could lead to potentially effective targeted therapies. To report the advances in the discovery of new biomarkers for HNSCC, and review the potential utility of biomarkers in the molecular diagnosis of HNSCC. A review of the English literature (PubMed) from 1980 to 2009. At present, the most widely accepted biomarker for HNSCC is high-risk HPV status. EGFR is another promising biomarker; however, further research is necessary to determine its prognostic benefit. A large number of promising biomarker candidates are now being evaluated, including epigenetic, expression and genomic-based markers. Studies to validate the sensitivity and specificity of these biomarkers in clinical samples from adequately powered prospective cohorts are needed for successful translation of these findings into potential molecular diagnostic, prognostic and therapeutic biomarkers for HNSCC.

AB - Head and neck squamous cell carcinoma (HNSCC) is a debilitating and lethal disease. Despite significant advances in radiotherapy and surgical management, the 5-year survival rate for head and neck cancer has remained a dismal 50%. Advances in early detection have been made, but to improve patient outcomes better biomarkers and targeted therapeutic agents are needed. New biomarkers can improve early detection and provide data to optimize therapeutic strategy and patient survival, and could lead to potentially effective targeted therapies. To report the advances in the discovery of new biomarkers for HNSCC, and review the potential utility of biomarkers in the molecular diagnosis of HNSCC. A review of the English literature (PubMed) from 1980 to 2009. At present, the most widely accepted biomarker for HNSCC is high-risk HPV status. EGFR is another promising biomarker; however, further research is necessary to determine its prognostic benefit. A large number of promising biomarker candidates are now being evaluated, including epigenetic, expression and genomic-based markers. Studies to validate the sensitivity and specificity of these biomarkers in clinical samples from adequately powered prospective cohorts are needed for successful translation of these findings into potential molecular diagnostic, prognostic and therapeutic biomarkers for HNSCC.

KW - Biomarkers

KW - Diagnosis

KW - DNA methylation

KW - Epidermal growth factor receptor

KW - Epigenetics

KW - Head and neck cancer

KW - Human papillomavirus

KW - Loss of heterozygosity

KW - MicroRNA

KW - Molecular biology

KW - Proteomics

KW - RNA

UR - http://www.scopus.com/inward/record.url?scp=77953452311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953452311&partnerID=8YFLogxK

U2 - 10.1517/17530050903338068

DO - 10.1517/17530050903338068

M3 - Article

C2 - 20161611

AN - SCOPUS:77953452311

VL - 4

SP - 53

EP - 65

JO - Expert Opinion on Medical Diagnostics

JF - Expert Opinion on Medical Diagnostics

SN - 1753-0059

IS - 1

ER -